Undisclosed p53 pathway program (Nested Therapeutics)

Nested Therapeutics is developing a mutation-selective allosteric small molecule targeting a transcriptional regulator within the p53 pathway. This program focuses on a novel cryptic pocket on the target protein, allowing for the selective modulation of mutant forms that are frequently found in various cancers. By binding to this specific site, the drug aims to restore or modify the pathway's activity in p53-mutant tumor cells while sparing wild-type function. The asset is currently in the lead optimization stage of preclinical development for the treatment of p53-mutant solid tumors.

Other names

Transcriptional regulator in p53 pathway (mutation-selective allosteric target in a cryptic pocket)